Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DEPARTURE: Durvalumab ± Tremelimumab with Carbon-Ion Radiotherapy in Advanced Hepatocellular Carcinoma with Macrovascular Invasion
jRCT2031210046Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Jul 2021
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of durvalumab and tremelimumab in hepatocellular carcinoma (HCC) (2 cohorts), sponsored by AstraZeneca. Primary endpoint: AEs/SAEs including DLTs. Started Jul 2021; status: completed.
02
Drugs
durvalumabtremelimumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on jRCT2031210046.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210046.